

Phone: 541-269-7400 Fax: 541-269-7147



idging the Future of Healthcare

## **Direct Oral Anticoagulants Drug Use Criteria**

Created: October 2016

Reviewed: 4/22/19, 12/9/21, 3/25/24, 2/14/25

Includes:

Xarelto© Rivaroxaban
Pradaxa© Dabigatran
Savaysa© Edoxaban

This drug use criteria will be used to determine ongoing coverage of the direct oral anticoagulants following the initial six months of therapy allowed through the Advanced Health formulary.

### **Guideline for Use:**


- 1. Does the member have an OHP funded condition?
  - a. If yes, continue to question 2.
  - b. If no, deny as BTL.
- 2. Does the member have a diagnosis for any of the recommended FDA approved indications (DVT or PE treatment, secondary prevention of recurrent DVT or PE, prophylaxis of DVT in knee or hip replacement surgery, or prevention of stroke or systemic embolism in nonvalvular atrial fibrillation), AND is the appropriate dose of medication being prescribed consistent with the FDA approved prescribing information?
  - a. If yes, continue to question 3
  - b. If no, deny as not meeting criteria. Use of medications for off label indications is considered experimental and not a covered benefit on OHP.

### Indications and Dosing

	Xarelto©	Pradaxa©	Savaysa©	

<sup>\*\*</sup>Eliquis© (Apixaban) has been added to the Formulary, without a PA effective 2/14/2025\*\*

<sup>\*\*</sup>Note to reviewer: Please coordinate with prescriber prior to denying authorization request for inappropriate dosing to change to FDA approved dosing regimen.





**dvancedHealth**Phone: 541-269-7400 Fax: 541-269-7147

_				
	Deep vein thrombosis (DVT) or pulmonary embolism (PE) treatment Reduction in risk of recurrent DVT/PE	15 mg twice daily for 21 days followed by 20 mg once daily  10 mg once daily after initial 6 months of therapy	150 mg twice daily following at least 5 days of parenteral anticoagulation 150 mg twice daily	60 mg once daily following at least 5 days of parenteral anticoagulation  Not indicated
	Nonvalvular atrial fibrillation Postoperative DVT prophylaxis	20 mg once daily  10 mg once daily  • Knee: 12 days	150 mg twice daily 110 mg on day 1 then 220 mg	60 mg once daily  Not indicated
	(hip and knee replacement surgery)	• Hip: 35 days	once daily (hip replacement only)  • Minimum:10 days  • Maximum: 35 days (knee replacement: 10-14 days)	
	Prophylaxis of VTE in acutely ill patients (not at	10mg once daily • Total recommended		
	high risk of bleeding)	duration of 31 to 39 days		
	Peripheral artery disease, stable or Coronary artery disease, stable	2.5 mg twice daily in combination with 75-100 mg aspirin daily		

# Duration of therapy

Provoked DVT/PE	• 3 months
• Surgery	
• Nonsurgical transient risk factors: es	trogen
therapy, pregnancy, leg injury, flight	>8h

Phone: 541-269-7400 Fax: 541-269-7147



ridging the Future of Healthcare

Unprovoked DVT/PE	<ul> <li>Low to moderate bleeding risk: extended anticoagulation therapy (no stop date)</li> <li>High bleeding risk: 3 months</li> </ul>
VTE associated with cancer: LMWH is the preferred agent over VKA, Pradaxa, Xarelto, Eliquis, or Savaysa	Extended anticoagulation therapy (no stop date)

- 3. Does the member have any conditions in which the DOACs are not recommended or contraindicated? See chart below.
  - a. If yes, deny as not meeting criteria. Warfarin or LMWH are alternatives
  - b. If no, approve for appropriate duration of therapy for FDA approved indication medication is prescribed to treat.

	VU-6	Darata a G	<b>C</b> 6
	Xarelto©	Pradaxa©	Savaysa©
Contraindication	-Active bleeding	-Active bleeding	-Active bleeding
		-Mechanical	
		prosthetic heart	
		valve	
Use not	-Prosthetic heart	-Bioprosthetic	-Age <18 years
recommended	valves	heart valve	old
	-Severe renal	-Severe renal	-Mechanical
	impairment	impairment (CrCl	heart valve
	(CrCl <15	<15 ml/min)	-Moderate to
	ml/min)	-Pregnancy	severe mitral
	-Hepatic	-Nursing mothers	stenosis
	impairment	-Triple positive	-CrCl >95 ml/min
	(Child-Pugh B	antiphospholipid	(nonvalvular
	and C)	syndrome	atrial fibrillation)
	-Hepatic disease	- GI/Bariatric	-Nursing
	associated with	surgery	mothers
	coagulopathy	(decreased	-Moderate to
	-Pregnancy	absorption)	severe hepatic
	-Nursing		impairment
	mothers		(Child-Pugh B
	-Prosthetic heart		and C)
	valves		-Triple positive
	-Triple positive		antiphospholipid
	antiphospholipid		syndrome
	syndrome		- GI/Bariatric
	- GI/Bariatric		surgery
	surgery		(decreased
	(decreased		absorption)
	absorption)		



Phone: 541-269-7400 Fax: 541-269-7147

Drug-Drug	-Anticoagulants	-Anticoagulants	-Anticoagulants
Interactions	-Combined P-gp	-Rifampin	-Rifampin
	and strong	-P-gp inducers	
	CYP3A4		
	inhibitors and		
	inducers		

<sup>\*</sup>Example of potential drug-drug interactions:

- -Strong CYP3A4 and P-gp Inducers: carbamazepine, phenytoin, rifampin, St. John's wort
- -Strong CYP3A4 and P-gp Inhibitors: cobicistat, conivaptan, danoprevir/ritonavir, elvitegravir/ritonavir, ketoconazole, clarithromycin, diltiazem, quinidine, tacrolimus, grapefruit juice

\*Note: The International society on Thrombosis and Haemostatis (ISTH) 2016 guideline suggests avoiding the use of DOACs in patients with BMI >40 kg/m2 or weight >120 kg due to lack of clinical data in this population. If used in patients with BMI >40 kg/m2 or weight >120 kg, ISTH suggests measuring peak and trough levels using an anti-factor Xa assay or mass spectrometry. If drug level is below expected range, ISTH recommends changing to Vitamin K antagonist. Advanced Health will not restrict access to DOAC medication based on BMI or weight, however, a note will be sent to the requesting provider alerting them to the lack of clinical data in this population.

### Rationale:


Due to high cost of therapy and potential for serious adverse events, drug use criteria help to promote safe, evidence-based prescribing of the direct oral anticoagulants.


### **FDA Approved Indications:**

Xarelto© (rivaroxaban) is FDA indicated for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), reduction in the risk of recurrence of DVT and PE, reduction of risk of stroke and systemic embolism in patient with nonvalvular atrial fibrillation, and prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients, and to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

Savaysa© (edoxaban) if FDA indicated for reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and the treatment of DVT and PE following 5-10 days of initial therapy with a parenteral anticoagulant.

Pradaxa© (dabigatran) is FDA indicated in adults for the reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment of DVT and PE following 5-10 days of initial therapy with a parenteral anticoagulant, reduction in the risk of recurrence of DVT and PE, and DVT and PE prophylaxis in patients that have undergone hip replacement surgery. Pradaxa© is FDA indicated in pediatric patients 8 to less than 18 years of age for the treatment of venous







\_\_\_\_\_

thromboembolic events who have been treated with a parenteral anticoagulant for at least 5 days and to reduce the risk of recurrence of VTE.

Eliquis© (apixaban) is FDA indicated for reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery, treatment of DVT and PE, and reduction in the risk of recurrent DVT and PE.

#### **References:**

- 1. Xarelto© Prescribing Information. Last updated 8/2021
- 2. Savaysa© Prescribing Information. Last updated 9/2016
- 3. Pradaxa© Prescribing Information. Last updated 6/2021
- 4. Eliquis© Prescribing Information. Last updates 7/2016
- 5. Kearin C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. CHEST 2016; 149(2):315-352
- 6. International Society on Thrombosis Haemostasis (ISTH) 2016 Guideline